Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia
Nonsense mutations leading to premature stop codons are common occurring in approximately 12% of all human genetic diseases. Thus, pharmacological nonsense mutation suppression strategies would be beneficial to a large number of patients if the drugs could be targeted to the affected tissues at the...
Main Authors: | Xia Wang, Kevin Gregory-Evans, Kishor M. Wasan, Olena Sivak, Xianghong Shan, Cheryl Y. Gregory-Evans |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-06-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2162253117301725 |
Similar Items
-
Nonsense suppression induced readthrough of a novel PAX6 mutation in patient‐derived cells of congenital aniridia
by: Xiaoliang Liu, et al.
Published: (2020-05-01) -
Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes
by: Valentino Bezzerri, et al.
Published: (2020-06-01) -
Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia
by: Celia Djayet, et al.
Published: (2021-12-01) -
Identification of a novel frameshift mutation in PAX6 gene and the clinical management in an Asian Indian aniridia family
by: Isham Palayil, et al.
Published: (2018-01-01) -
PAX6 gene analysis in Serbian patients with aniridia
by: Cvetković Dimitrije, et al.
Published: (2016-01-01)